Phase 2/3 trial

BOSTON, July 17, 2026 Compass Therapeutics, Inc. announced that Phase 2/3 clinical data from its investigational DLL4 × VEGF-A...

New Haven, Conn., July 17, 2026 Veradermics announced the presentation of new subgroup analysis data from its Phase 2/3...

San Francisco, California, USA – April 22, 2026 In a significant advancement for rare cardiac disease therapeutics, Thryv Therapeutics...

MALVERN, Pa., USA — April 1, 2026 Ocugen, Inc. has announced the early completion of dosing in its Phase...

South San Francisco, California, USA | March 22, 2026 IDEAYA Biosciences has announced updated guidance on the anticipated topline...